1Manns MP,Foster GR,Rockstroh JK,et al.The way forward in HCV treatment--finding the right path[J].Nat Rev Drug Diseov,2007,6(12):991-1000.
2Gao M,Nettles RE,Belema M,et al.Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect[J].Nature,2010,465(7294):96-100.
3Kwo PY,Vinayek R.The therapeutic approaches for hepatitis C virus:protease inhibitors and polymerase inhibitors[J].Gut Liver,2011,5(4):406-417.
4Butt AA,Kanwal F.Boceprevir and telaprevir in the management of hepatitis C virus-infected patients[J].Clin Infect Dis,2012,54(1):96-104.
5Sarrazin C,Berg T,Cornberg M,et al.Expert opinion on boce-previr-and telaprevir-based triple therapies of chronic hepatitis C[J].Z Gastroenterol,2012,50(1):57-72.
6Vallet S,Viron F,Henquell C,et al.NS3protease polymorphism and natural resistance to protease inhibitors in French patients in-fected with HCV genotypes1-5[J].Antivir Ther,2011,16(7):10931102.
7Stoltz JH,Stern JO,Huang Q,et al.A twenty-eight-day mechanistic time course study in the rhesus monkey with hepatitis C virus protease inhibitor BILN2061[J].Toxicol Pathol,2011,39(3):496501.
8Massariol MJ,Zhao S,Marquis M,et al.Protease and helicase activities of hepatitis C virus genotype4,5,and6NS3-NS4A protein[sJ].Biochem Biophys Res Commun,2010,391(1):692-697.
10Lange CM,Susser S,Herrmann E,et al.HVR-1heterogeneity during treatment with telaprevir with or without pegylated interferon alfa-2a[J].Scand J Gastroenterol,2011,46(11):1362-1368.
